GS101

GS101 is a biosimilar candidate of dupilumab, a recombinant human IgG1 monoclonal antibody developed by Jiangsu Genscend Biopharmaceutical. It acts as an antagonist to the interleukin-4 receptor alpha (IL-4Rα) subunit, which is shared by the interleukin-4 (IL-4) and interleukin-13 (IL-13) receptor complexes. By binding to IL-4Rα, GS101 inhibits the signaling of IL-4 and IL-13, two key cytokines that drive type 2 inflammation, which is central to the pathogenesis of atopic dermatitis and other allergic diseases. Currently, GS101 is being evaluated in a Phase 3 comparative clinical trial to demonstrate therapeutic equivalence in efficacy and safety to the reference product, Dupixent, in patients with moderate-to-severe atopic dermatitis.

Other names

GS101 injectionGS-101 injectionGS 101 injection